Monthly subcutaneous injections of galcanezumab at either 120 mg or 300 mg were effective for preventing migraines.
The use of intranasal sumatriptan is an effective treatment for patients with acute migraine attacks; however, future investigations are needed to better understand differences in routes of administration and other therapies for migraine.
A recent study by Doulberis and colleagues provides a comprehensive summary of the relevant published studies linking migraine and gastrointestinal or related disorders.
Cefaly Technology announced that the FDA has cleared for use the Cefaly Acute medical device for the treatment of migraines, with or without aura, in patients ≥18 years of age.
Even though there's a variety of migraine subtypes on the books, there are two major subtypes: migraine without aura (characterized with specific features and associated symptoms) and migraine with aura (transient neurological symptoms that proceed or accompany a headache).
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics